Final Guidance On Non-Inferiority Studies Lacks Industry-Sought Changes
One of industry's central concerns about the US FDA’s 2010 draft guidance was a "vaguely" and "subjectively" defined M2 clinical margin, but FDA did not provide a new definition in the finalized version.
You may also be interested in...
Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.